Cassava Sciences shares fall
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials.
Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines
Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the Alzheimer's drug simufilam, and agreed to pay fines.
SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements
The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer’s clinical trial
The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former executives for misleading claims about the results of Alzheimer’s clinical trials.
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial.
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic treatment of Alzheimer's disease, the Securities and Exchange Commission said on Thursday.
Cassava Sciences Resolves SEC Investigation
Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented remedial ...
Why I'm Avoiding Cassava Stock For Now
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
Stocks to Watch: Cassava Sciences, Scholastic, MeridianLink
MeridianLink announced an underwritten secondary public offering of 6 million shares by funds managed by Thoma Bravo. The selling stockholders plan to grant the underwriter an option to purchase up to ...
Cassava Sciences Unusual Options Activity For September 23
Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Morningstar13h
News Highlights: Top Company News of the Day - Thursday at 9 PM ET
30, while Smartmatic has a separate suit pending against Fox News. Cassava Sciences settles SEC charges of 'misleading' Alzheimer's trial claims Shares of Cassava Sciences Inc. dropped more ...
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...
Pharmaceutical Technology3d
Cassava Sciences gets grant for pharmaceutical composition of crystalline and amorphous compounds
Discover how Cassava Sciences Inc. secures a patent for innovative pharmaceutical compositions using crystalline and amorphous polymorphs, enhancing therapeutic efficacy.